FIXX 17,69$
- im Depot von BB Biotech vertreten
https://www.technologyreview.com/s/608749/...-editing-without-crispr/
Zahlen für Q1/21
- Umsatz 29 Mio. $ (Kollaborationszahlungen von Novartis & Pfizer)
- Verlust 1 Mio. $
- Cash 189 Mio. $
- MK 364 Mio. $
to fund operations into the first quarter of 2023
- On Track to Report Initial Phase 2 Data From pheNIX PKU Clinical Trial by Year End -
https://investors.homologymedicines.com/...ter-2021-financial-results
Zahlen für Q2/21
- Umsatz 2 Mio. $
- Verlust 31 Mio. $
- Cash 213 Mio. $
- MK 391 Mio. $
Homology expects cash resources to fund operations into the first quarter of 2023
- On Track to Report Initial Results from Phase 2 pheNIX Gene Therapy Trial for Adults with PKU in 2021
- Plans to Initiate First-Ever Gene Editing Trial for PKU with HMI-103 This Year
- Expects to Commence Clinical Trial with HMI-203 In Vivo Gene Therapy Candidate for MPS II by Year End
https://investors.homologymedicines.com/...ter-2021-financial-results
Zahlen für Q3/21
- Umsatz 2 Mio. $
- Verlust 31 Mio. $
- Cash 188 Mio. $
- MK 313 Mio. $
Homology continues to expect cash resources to fund operations into the first quarter of 2023.
https://investors.homologymedicines.com/...ter-2021-financial-results
Deal mit Oxford Biomedica
- 130 Mio. $ Cash
https://www.fiercebiotech.com/biotech/...-to-fund-gene-therapy-trials
FDA verhängt einen klinischen Stop für HMI-102
https://investors.homologymedicines.com/...-phenix-gene-therapy-trial
Zahlen für Q4/21
- Umsatz 0,8 Mio. $
- Verlust 34 Mio. $
- Cash 156 Mio. $
- MK 183 Mio. $
"Based on current projections, Homology expects current cash resources, including the $130.0 million received from Oxford Biomedica in March 2022, to fund operations into the second half of 2024"
https://investors.homologymedicines.com/...quarter-and-full-year-2021
Ich denke, dass das Chancen-Risiko-Verhältnis hier mindestens ausgelichen ist. Derzeit liegt der Cashbestand (~285 Mio. $) deutlich über der MK, zudem ist FIXX bis ins Jahr 2024 durchfinanziert.
FDA hebt den klinischen Stop der Gentherapiestudie HMI-102 (PKU) auf
- siehe Posting #35
https://www.homologymedicines.com/news-story/...therapy-trial-for-pku
Zahlen für Q3/22
- Umsatz 1 Mio. $
- Verlust 34 Mio. $
- Cash 201 Mio. $
- MK 110 Mio. $
- fund operations into the fourth quarter of 2024
https://investors.homologymedicines.com/...ter-2022-financial-results
Zahlen für Q4/22
- Umsatz 0,8 Mio. $
- Verlust 34 Mio. $
- Cash 175 Mio. $
- MK 63 Mio. $
- expects current cash resources to fund operations into the fourth quarter of 2024
https://investors.homologymedicines.com/...quarter-and-full-year-2022
Zahlen für Q1/23
- Umsatz 1 Mio. $
- Verlust 34 Mio. $
- Cash 175 Mio. $
- MK 49 Mio. $
- fund operations into the fourth quarter of 2024
https://investors.homologymedicines.com/...quarter-and-full-year-2022
prüft strategische Alternativen
https://investors.homologymedicines.com/...evaluate-strategic-options